Spago Nanomedical plans to delist its shares from Nasdaq First North
The Swedish biotech company intends to apply for delisting, subject to an extraordinary shareholder meeting vote on 19 November 2026.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swedish company Spago Nanomedical AB (publ) intends to request the removal of its shares from trading on Nasdaq First North. The move depends on approval at an extraordinary general meeting scheduled for 19 November 2026. According to TradingView, the last trading day is expected in February 2027.
Major shareholders, who hold about 65% of the capital, have signaled support for the proposal. The company frames the step as part of a plan to finance Phase IIa of its Tumorad program after limited public fundraising.
why it matters
Leaving the exchange typically reduces liquidity and can weigh on a stock's valuation, so minority holders should note the timeline for closing trades. If the company raises capital privately, public shareholders face a greater risk of dilution later. No plans to relist have been stated.
tags
instruments
sources
- Spago Nanomedical AB (publ) (SPAGO) To Seek Delisting Pending EGM — TradingView, 22 October 2026 at 17:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗